Microphysiological Systems for Dissection of Host - Microbiota Interaction, Disease Modelling and Drug Screening 

Liver-on-chip Publications

Rennert K., Steinborn S., Gröger M., Ungerböck B., Jank A.M., Ehgartner J., Nietzsche S., Dinger J., Kiehntopf M., Funke H., Peters F.T., Lupp A., Gärtner C., Mayr T., Bauer M., Huber O., Mosig A.S; A microfluidically perfused three dimensional human liver model. Biomaterials, 2015, 71:119-131 

Gröger M., Dinger J., Kiehntopf M., Peters F.T., Rauen U., Mosig A.S.; Preservation of Cell Structure, Metabolism and Biotransformation Activity of Liver-on-chip Organ Models by Hypothermic Storage. Advanced Healthcare Materials, 2017, Jan;7(2): 1700616-1700630 

Gröger M., Rennert K., Giszas B., Weiß E., Dinger J., Funke H., Kiehntopf M., Peters F.T., Lupp A., Bauer M., Claus RA., Huber O., Mosig AS.; Monocyte-induced recovery of inflammation-associated hepatocellular dysfunction in a biochip-based human liver model. Scientific Reports, 2016, 6: 21868 - 21884

Pein H., Ville A., Pace S., Temml V., Garscha U., Raasch M., Alsabil K., Viault G., Dinh CH., Guilet D., Troisi F., Neukirch K., König S., Bilancia R., Waltenberger B., Stuppner H., Wallert M., Lorkowski S., Weinigel C., Rummler S., Birringer M., Roviezzo F., Sautebin L., Helesbeux J.J., Séraphin D., Mosig A.S., Schuster D.,  Rossi A., Richomme P., Werz O., Koeberle A.; Endogenous metabolites of vitamin E limit inflammation by targeting 5‑lipoxygenase.Nature Communications, 2018, 9(1):3834 –3851 

Press A.T., Traeger A., Pietsch C., Mosig A.S., Wagner M., Clemens M.G., Jbeily N., Koch N., Gottschaldt M., Bézière N., Ermolayev V., Ntziachristos V., Popp J., Kessels M., Qualmann B., Schubert U.S., Bauer M; Cell type-specific delivery of short interfering RNAs by dye-functionalized "theranostic“ nanoparticles. Nature Communications, 2014, 5:5565-5578 

Blaurock-Möller N., Gröger M., Siwczak F., Dinger J., Schmerler D., Mosig A.S.*, Kiehntopf M.* (* shared senior authorship); CAAP48, a new sepsis biomarker, induces hepatic dysfunction in an in vitro liver-on-chip model. Frontiers in Immunology, 2019, Feb 25;10:273. doi: 10.3389/fimmu.2019.00273 

Fahrner R., Möller A., Press AT., Kortgen A., Kiehntopf M.D., Rauchfuss F., Settmacher U., Mosig A.S.; Short-term treatment with taurolidine is associated with liver injury. BMC Pharmacology and Toxicology, 2017, 18(1):61-70 

Raasch M., Fritsche E., Kurtz, A., Bauer M., Mosig A.S.; Microphysiological systems meet hiPSC technology - new tools for disease modeling of liver infections in basic research and drug development. Advanced Drug Delivery Reviews, 2018, Jun 15, pii: S0169-409X(18)30147-9. doi: 10.1016/j.addr.2018.06.008 – Impact Factor 13,66

Ryabchykov O., Bräutigam K., Galler K., Neugebauer U., Mosig A.S., Bocklitz T., Popp J; Characterization of the unique human liver cell line HepaRG by Raman microspectroscopy. Journal of Raman Spectroscopy, 2018, 49: 935-942 

Mann A., Pelz T., Rennert K., Mosig A.S., Decker M., Lupp A.; Evaluation of HepaRG cells for the assessment of indirect drug-induced hepatotoxicity using INH as a model substance. Human Cell, 2017 May 19:267-278 

Rennert K., Otto P., Funke H., Huber O., Tomaso H., Mosig A.S.; A human macrophage - hepatocyte co-culture model for comparative studies of infection and replication of Francisella tularensis LVS strain and subspecies holarctica and mediasiatica. BMC Microbiology, 2016,16(1):2-12